What we do
CEPI leverages its unique position within the global health and R&D ecosystems to address market failures, building on its track record of bringing together public-sector, private-sector, and academic partners to accelerate the development of vaccines against emerging viral threats.
30+
Number of investors, from governments to philanthropies, who have donated to CEPI
Up to $3.1 bn
Invested in R&D&M projects since CEPI's launch
180+
Partnerships established to develop vaccines and biologics against CEPI's priority pathogens
Priority pathogens
CEPI supports the development of vaccines, platform technologies and manufacturing innovations to combat priority pathogens for which no licensed vaccines are currently available.
Research and development
CEPI is leading a broad range of ambitious programmes that aim to substantially reduce global epidemic and pandemic risk.
Manufacturing and supply chain
CEPI is bolstering global manufacturing capacity in underserved regions and harnessing innovative technologies to improve the speed, scale and access of vaccine manufacturing in response to epidemic and pandemic threats.
Calls for Proposals
Innovators worldwide are invited to apply to our scientific programmes to advance the development and manufacture of vaccines and tools against epidemic and pandemic threats.
Our portfolio
Since our launch in 2017, CEPI has carefully selected and announced over 50 partnerships to advance vaccine candidates against our priority pathogens and platform technologies for use against Disease X.
View our portfolio
Our impact
CEPI has backed the development of 30+ vaccine candidates for its priority pathogens, overseeing scientific breakthroughs, including the first-ever approved Chikungunya vaccine, and advancing the first-ever Nipah vaccine into Phase I and the first-ever Lassa fever vaccine into Phase II trials. A key player in the COVID-19 response, CEPI also has one of the world’s largest COVID-19 vaccine portfolios and co-led COVAX, which helped to distribute nearly 2 billion doses to 146 nations.
Impact Stories
Latest News
Latest News
Richard Hatchett reflects on a “banner year for viruses” and looks ahead to 2025
In his end-of-year message, CEPI's CEO, Dr Richard Hatchett, reflects on a "banner year for viruses" and explores the trends, innovations and technologies that are shaping the future of global health.
Valneva expands access to Asia for its chikungunya vaccine with Serum
The collaboration to support broader vaccine access to the region falls within the agreement between Valneva and CEPI with co-funding from the EU.
Establishing vaccine safety benchmarking in Africa for African vaccines
Consortium is set to further establish a vaccine safety evidence-generation network in Africa, seeking to understand prevalence of anticipated adverse events specifically relevant to African populations.
Scientists launch largest-ever study tracking chikungunya burden in East Africa
Led by the University of Oxford, researchers are set to investigate the number of children and adults affected by chikungunya in Kenya and Tanzania.
Transatlantic scientists to transition traditional vaccine development onto rapid-response platform for faster outbreak control
Partnership could speed up parts of the vaccine development process by several months and save over £1 million in development costs
